Recent Updates
Recently added Catalysts
VRDN Positive Sentiment

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Wednesday, September 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Viridian Therapeutics, a biotechnology firm, will participate in the Wells Fargo 21st Annual Healthcare Conference. Senior management is scheduled for a fireside chat on September 8, 2026. This event will be accessible via a live webcast, showcasing the company's commitment to transparency and investor engagement.

Market Sentiment Analysis

POSITIVE FACTORS

  • Viridian Therapeutics is actively engaging with investors.
  • Participation in a prominent healthcare conference highlights company visibility.
  • The event could lead to potential partnerships and funding opportunities.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+77%
120-day peak, hindsight
Typical move
3.7%
average across 5 past catalysts
Cash runway
~27 mo
Minimal dilution risk
Lead asset
Veligrotug
Phase 3 · Thyroid Eye Disease

Full Press Release Details

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 12:45pm ET. A live webcast of the fireside chat can be accessed under “Events and Presentations” on the Invest

Frequently Asked Questions

When will Viridian participate in the conference?

Viridian will participate in the conference on September 8, 2026.

What type of event is the Wells Fargo conference?

It is the 21st Annual Healthcare Conference.

How can I access the fireside chat?

The fireside chat will be available via a live webcast.

Who will represent Viridian at the conference?

Senior management from Viridian Therapeutics will participate.

ShareAdd on Google
Tags: VRDN Viatris Investor Conferences Healthcare Viridian Therapeutics Wells Fargo healthcare conference biotechnology
Last updated: Sep 2, 2026

Biotech snapshot

Cash runway
$982M liquidity · $35M/mo burn
~27 mo
Minimal dilution risk
Lead asset
VeligrotugPhase 3
Thyroid Eye Disease →

Catalyst track record

+77%
best trade around VRDN's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for VRDN.

See every catalyst's timing & PoA →